
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT
- About


McKesson Corporation (MCK)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: MCK (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Year Target Price $732.45
Year Target Price $732.45
10 | Strong Buy |
3 | Buy |
3 | Hold |
0 | Under performing |
1 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit 47.12% | Avg. Invested days 72 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 90.65B USD | Price to earnings Ratio 28.25 | 1Y Target Price 758.57 |
Price to earnings Ratio 28.25 | 1Y Target Price 758.57 | ||
Volume (30-day avg) - | Beta 0.49 | 52 Weeks Range 462.92 - 736.36 | Updated Date 06/29/2025 |
52 Weeks Range 462.92 - 736.36 | Updated Date 06/29/2025 | ||
Dividends yield (FY) 0.39% | Basic EPS (TTM) 25.69 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 0.92% | Operating Margin (TTM) 1.53% |
Management Effectiveness
Return on Assets (TTM) 4.31% | Return on Equity (TTM) - |
Valuation
Trailing PE 28.25 | Forward PE 19.46 | Enterprise Value 92351608837 | Price to Sales(TTM) 0.25 |
Enterprise Value 92351608837 | Price to Sales(TTM) 0.25 | ||
Enterprise Value to Revenue 0.26 | Enterprise Value to EBITDA 17.56 | Shares Outstanding 124904000 | Shares Floating 124900796 |
Shares Outstanding 124904000 | Shares Floating 124900796 | ||
Percent Insiders 0.06 | Percent Institutions 90.26 |
Analyst Ratings
Rating 4.29 | Target Price 732.45 | Buy 3 | Strong Buy 10 |
Buy 3 | Strong Buy 10 | ||
Hold 3 | Sell 1 | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
McKesson Corporation

Company Overview
History and Background
McKesson Corporation was founded in 1833 as Olcott McKesson & Co. It has evolved from a drug import and wholesale business to a global leader in healthcare supply chain management solutions, retail pharmacy, and healthcare technology.
Core Business Areas
- U.S. Pharmaceutical and Specialty Solutions: Distributes pharmaceutical products, provides specialty pharmaceutical services, and offers technology solutions to pharmacies, hospitals, and healthcare providers across the United States.
- International: Offers pharmaceutical distribution, retail pharmacy services, and healthcare technology solutions in Europe and other international markets.
- Medical-Surgical Solutions: Distributes medical-surgical supplies, equipment, and logistics services to healthcare providers, including hospitals, surgery centers, and physician offices.
Leadership and Structure
McKesson is led by CEO Brian Tyler. The organizational structure includes various business units and functional departments, operating under a board of directors.
Top Products and Market Share
Key Offerings
- Pharmaceutical Distribution: McKesson distributes a wide range of pharmaceutical products. Competitors include AmerisourceBergen and Cardinal Health. Market share is significant, estimated around 25% of the US market.
- Medical-Surgical Distribution: Distributes medical and surgical supplies and equipment. Competitors include Cardinal Health and Owens & Minor. Market share is substantial, making it a major player in this segment.
- Retail Pharmacy Solutions: Provides solutions for retail pharmacies, including technology and services. Competitors include CVS Health and Walgreens Boots Alliance.
Market Dynamics
Industry Overview
The healthcare distribution industry is characterized by high regulation, consolidation, and increasing demand driven by aging populations and technological advancements. Profitability is influenced by drug pricing pressures and supply chain efficiencies.
Positioning
McKesson is a leading player in the healthcare supply chain, holding a significant market share in pharmaceutical and medical-surgical distribution. Competitive advantages include its scale, established relationships, and integrated solutions. McKesson can benefit from both organic growth and from small strategic acquisitions.
Total Addressable Market (TAM)
The global healthcare supply chain market is estimated to be over $2 trillion. McKesson's positioning as a leading distributor and solutions provider allows it to capture a significant portion of this TAM.
Upturn SWOT Analysis
Strengths
- Large market share
- Extensive distribution network
- Strong relationships with suppliers and customers
- Diversified product and service offerings
- Global presence
Weaknesses
- Exposure to drug pricing pressures
- Dependence on key suppliers
- Legal and regulatory risks
- Low profit margins compared to other industries
- Debt Leverage
Opportunities
- Expanding into new markets and geographies
- Acquiring smaller competitors
- Developing innovative healthcare solutions
- Leveraging data analytics and technology
- Growth in biosimilars and specialty drugs
Threats
- Increased competition
- Changes in healthcare regulations
- Economic downturns
- Supply chain disruptions
- Cybersecurity threats
Competitors and Market Share
Key Competitors
- ABC
- CAH
Competitive Landscape
McKesson competes with other large pharmaceutical distributors and healthcare technology companies. Its strengths include its scale and integrated solutions. Weaknesses include exposure to drug pricing pressures. Competitors such as ABC have comparable scale and distribution networks, making the market highly competitive.
Major Acquisitions
CoverMyMeds
- Year: 2017
- Acquisition Price (USD millions): 1100
- Strategic Rationale: Expanded McKesson's technology solutions for pharmacies and patients.
Growth Trajectory and Initiatives
Historical Growth: McKesson has experienced steady growth in revenue, driven by acquisitions and organic expansion. However, profitability has been impacted by drug pricing pressures.
Future Projections: Analysts project continued growth in revenue and earnings, driven by increasing healthcare spending and strategic initiatives.
Recent Initiatives: Recent initiatives include investments in technology, expansion into new markets, and acquisitions of smaller companies.
Summary
McKesson is a strong player in the healthcare supply chain, benefiting from its scale and established relationships. Its pharmaceutical distribution business is a key strength, and investments in technology are promising. However, drug pricing pressures and regulatory risks pose challenges.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Industry Reports (e.g., IBISWorld)
- Analyst Reports (e.g., Morningstar, S&P Capital IQ)
- Company Website
- Market Research Reports
Disclaimers:
This analysis is based on publicly available information and analyst estimates. Investment decisions should be based on individual risk tolerance and thorough due diligence. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About McKesson Corporation
Exchange NYSE | Headquaters Irving, TX, United States | ||
IPO Launch date 1994-11-15 | CEO & Director Mr. Brian S. Tyler Ph.D. | ||
Sector Healthcare | Industry Medical Distribution | Full time employees 43000 | Website https://www.mckesson.com |
Full time employees 43000 | Website https://www.mckesson.com |
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The RxTS segment serves biopharma and life sciences partners to address challenges for patients by working across healthcare to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies to deliver solutions to help people get the medicine needed to live healthier lives; and provides medication access and affordability, prescription decision support, prescription price transparency, benefit insight, dispensing support, third-party logistics, and wholesale distribution support services, as well as electronic prior authorization services. The Medical-Surgical Solutions segment offers medical-surgical supply distribution, logistics, biomedical maintenance, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, post-acute care facilities, hospital reference labs, and home health care agencies. The International segment delivers deliver medicines, supplies, and information technology solutions to retail pharmacies, hospitals, long-term care centers, clinics and institutions; and provides logistics and distribution services for manufacturers. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.